Revenue: As of FY2026 Q1, the actual value is USD 8.002 M, beating the estimate of USD 7.6 M.EPS: As of FY2026 Q1, the actual value is USD -0.31, missing the estimate of USD -0.2467.EBIT: As of FY2026 Q1, the actual value is USD -13.47 M.Rapid Micro Biosystems, Inc. operates as a single reportable segment. All figures are for the three months ended March 31, 2026, compared to the three months ended March 31, 2025, and are in thousands, unless otherwise specified.<h4>Revenue</h4><ul><li>Total revenue increased by $797, or 11.1%, to $8,002 from $7,205.</li><li>Product revenue increased by $1,477, or 36.0%, to $5,578 from $4,101, primarily due to increased system placements and higher consumable shipment volumes.</li><li>Service revenue decreased by $680, or -21.9%, to $2,424 from $3,104, mainly due to lower validation revenue, partially offset by higher service contract revenue.</li><li>Recurring revenue increased by $1,100, or 27.7%, to $5,069 from $3,969, representing 63.3% of total revenue in 2026 compared to 55.1% in 2025.</li><li>Non-recurring revenue decreased to $2,933 from $3,236.</li><li>Revenue by customer geography:<ul><li>United States revenue increased to $2,471 from $2,026.</li><li>Switzerland revenue decreased to $1,367 from $1,480.</li><li>South Korea revenue significantly increased to $1,278 from $52.</li><li>Germany revenue decreased to $889 from $1,309.</li><li>Japan revenue decreased to $417 from $1,124.</li><li>All other countries revenue increased to $1,580 from $1,214.</li></ul></li></ul><h4>Operational Metrics</h4><ul><li>Total cost of revenue increased by $830, or 12.2%, to $7,631 from $6,801.<ul><li>Cost of product revenue increased by $996, or 19.8%, to $6,025 from $5,029.</li><li>Cost of service revenue decreased by $166, or -9.4%, to $1,606 from $1,772.</li></ul></li><li>Gross margin decreased by $33, or -8.2%, to $371 from $404.</li><li>Gross margin percentage was 5% in 2026, down from 6% in 2025.</li><li>Operating expenses increased by $2,158, or 17.9%, to $14,223 from $12,065.<ul><li>Research and development expenses decreased by $265, or -7.3%, to $3,359 from $3,624.</li><li>Sales and marketing expenses increased by $671, or 24.4%, to $3,422 from $2,751.</li><li>General and administrative expenses increased by $1,752, or 30.8%, to $7,442 from $5,690.</li></ul></li><li>Loss from operations increased to -$13,852 from -$11,661.</li><li>Net loss increased to -$14,275 from -$11,263.</li></ul><h4>Cash Flow</h4><ul><li>Net cash used in operating activities increased to -$15,058 from -$9,065.</li><li>Net cash provided by investing activities decreased to $8,596 from $10,681.</li><li>Net cash provided by financing activities decreased to $247 from $379.</li></ul><h4>Unique Metrics</h4><ul><li>Systems placed in the period increased to 6 from 3.</li><li>Cumulative systems placed increased to 196 from 165.</li><li>Systems validated in the period decreased to 5 from 9.</li><li>Cumulative systems validated increased to 160 from 146.</li></ul><h4>Future Outlook and Strategy</h4>Rapid Micro Biosystems, Inc. anticipates its current cash, investments, and borrowing capacity will fund operations and capital expenditures for at least twelve months from the financial statements’ issuance date. The company aims to achieve positive cash flow without additional financing by focusing on revenue growth, gross margin improvement, and operating cost control. However, if these assumptions are not met, the company may need to reduce spending or seek further funding, potentially delaying expansion plans.

Rapid Micro Biosystems | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 8.002 M